Multidisciplinary Approaches for Improving Patient Care in Pulmonary Arterial Hypertension: Advances in Therapeutic Selection

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the webinar held November 2, 2020

This activity is valid from February 1, 2021 to March 1, 2023

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder characterized by vascular remodeling of the pulmonary arteries which carry blood from the heart to the lungs. For those with PAH, the muscles within the arterial walls tighten, which often leads to a progressive increase in pulmonary vascular resistance that leads to right ventricular failure and significant morbidity and mortality. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure. About half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. There continue to be significant challenges in identifying and diagnosing PAH because it requires a combination of information based on symptoms, a physician examination, risk factors, and other findings based on previous tests. Evaluation typically include laboratory testing, echocardiography, pulmonary function testing, assessment of exercise capacity with six-minute walk distance or cardiopulmonary exercising testing, imaging, and a right heart catheterization among others.

The American College of Chest Physicians (ACCP) also published new treatment guidelines in 2019. There are a wide variety of treatment options to help manage PAH, including general measures, nonspecific pharmacologic intervention and targeted pharmacologic intervention. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Physicians must be able to make tailored treatment decisions for individual patients, based on their diagnosis and severity, for proper management. Optimal treatment, accurate classification, and risk stratification are keys to managing the patient’s health and costs, as incorrect classification can lead to inappropriate treatment decisions. The current guidance recommendations suggest that the optimal therapeutic approach for each patient must be personalized to take into account a patient’s severity, route of administration of therapy, adverse effect profiles, comorbidity, and achieving treatment goals. As such, patients require access to all indicated treatment options to optimize disease management.

Upon completion of this activity, participants will be able to:

  • Review the latest clinical evidence and guidelines for the best management of pulmonary arterial hypertension (PAH)

  • Discuss signs and symptoms of PAH to identify best practices for achieving an early and accurate diagnosis

  • Examine clinical data to show the safety and efficacy of treatments for PAH, including the use and effectiveness of combination therapies

  • Explore goal-directed strategies to effectively manage treatment, adherence, and adverse events

  • Assess effective management strategies for a patient-centered, multidisciplinary approach to care for and improve the quality of life in patients with PAH

     

Faculty: Steven Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University

Disclosure:

Dr. Nathan serves on the speaker’s bureau for Boerhinger-Ingelheim, Roche-Genentech, and Bayer. He serves as a consultant for Bayer, Boerhinger-Ingelheim, Bellephoron, Galapagos, Promedior, Roche, United Therapeutics, Third Pole, Altavant. He has received research funding from Bayer, Boerhinger-Ingelheim, and United Therapeutics. His presentation has been peer-reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue